Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 20, 2025 12:30 ET | Source: NanoNewron

NanoNewron and its Research to Advance the Treatment of Alzheimer’s Disease are Featured by Rutgers University Newsletters and on Rutgers Today

NanoNewron, a biotech company developing biologics crossing the blood-brain barrier to treat Alzheimer’s, was featured by Rutgers University Newsletters
August 30, 2023 08:30 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023

Additional biomarker data up to two years of treatment continue to demonstrate rapid and sustained normalization of CSF heparan sulfate to normal healthy levels and improvement in lysosomal function...
February 05, 2021 09:00 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics to Present New Data on ETV:IDS (DNL310) for the Potential Treatment of Hunter Syndrome at WORLDSymposium™

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to...
December 09, 2020 09:00 ET | Source: InvestorBrandNetwork (IBN)

InvestorBrandNetwork Announces Gamechangers LIVE Interview with CNS Pharmaceuticals Inc. Chairman & CEO John Climaco

LOS ANGELES, Dec. 09, 2020 (GLOBE NEWSWIRE) -- via InvestorWire — InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities, today announces...
November 10, 2020 07:30 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Announces First Human Biomarker Proof of Concept for Its Transport Vehicle (TV) Technology Achieved in Phase 1/2 Study of ETV:IDS (DNL310) in Hunter Syndrome (MPS II)

After four weekly intravenous doses of DNL310, a 76% mean reduction in CSF GAG levels (heparan sulfate) from baseline was observed, with normal healthy levels being achieved in four of five...
May 27, 2020 16:30 ET | Source: Denali Therapeutics Inc.

Denali Therapeutics Announces Publication of Two New Papers Describing Its Blood-Brain Barrier Delivery Technology in Science Translational Medicine

Denali’s “Transport Vehicle” technology enables broad distribution and improved exposure levels of therapeutic proteins throughout the brainClinical proof of concept data with DNL310 (ETV:IDS), the...
May 18, 2018 18:30 ET | Source: Voyager Therapeutics, Inc.

Voyager Therapeutics Announces Additional Data at the American Society of Gene and Cell Therapy 2018 Annual Meeting

Voyager’s gene therapy vector for Friedreich’s ataxia prevents central and peripheral disease progression in preclinical model out to one year after a single administration Durable safety data...
July 17, 2017 07:04 ET | Source: Voyager Therapeutics

Voyager Therapeutics Announces Publication from the California Institute of Technology of a Second-Generation Gene Therapy Capsid Demonstrating Further Enhanced Gene Transfer to the Brain

A single, intravenous administration of a novel AAV capsid provided up to 100-fold increase in gene transfer to the central nervous system in a preclinical model compared to the historical standard...